BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.49% | -112.78% | 29.54% | 48.62% | 17.78% |
| Total Depreciation and Amortization | -29.47% | -0.41% | -15.89% | -6.52% | 24.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.62% | 211.00% | 47.54% | -52.51% | 109.70% |
| Change in Net Operating Assets | -237.94% | 175.24% | -74.74% | -8.79% | -312.87% |
| Cash from Operations | -72.97% | 99.00% | 6.24% | -6.05% | -16.19% |
| Capital Expenditure | -43.15% | -66.35% | -1.99% | 14.14% | -5.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.03% | -484.19% | 139.31% | -111.96% | 4,060.19% |
| Cash from Investing | 87.17% | -2,528.36% | 55.41% | -136.96% | 572.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 96,271.43% | -99.91% | -- | -- | 63.89% |
| Repurchase of Common Stock | -24.08% | 82.32% | 68.26% | -689.96% | 16.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 96.89% |
| Cash from Financing | 245.55% | 52.88% | 88.13% | -1,456.38% | 100.57% |
| Foreign Exchange rate Adjustments | 64.95% | 124.13% | -116.31% | -156.55% | 186.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.65% | -78.01% | 55.73% | -60.37% | 190.12% |